Abivax Files 6-K, Signals Press Release Issued Jan 22, 2024
Ticker: AAVXF · Form: 6-K · Filed: Jan 22, 2024 · CIK: 1956827
| Field | Detail |
|---|---|
| Company | Abivax S.A. (AAVXF) |
| Form Type | 6-K |
| Filed Date | Jan 22, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: press-release, regulatory-filing, corporate-update
TL;DR
**Abivax just dropped a press release, check Exhibit 99.1 for the details!**
AI Summary
Abivax S.A., a pharmaceutical company, filed a 6-K on January 22, 2024, indicating they issued a press release on the same date. This filing itself doesn't contain the press release's content but signals that important news was released. Investors should seek out the attached Exhibit 99.1 to understand the specific details of the press release, as it likely contains material information that could impact the company's stock price and future prospects.
Why It Matters
This filing alerts investors that Abivax has released new information via a press release, which could contain significant updates about their drug development, financial performance, or strategic plans, potentially affecting the stock's value.
Risk Assessment
Risk Level: medium — The risk is medium because the filing itself is administrative, but the undisclosed content of the referenced press release could contain highly material information, positive or negative.
Analyst Insight
A smart investor would immediately locate and review Exhibit 99.1 to understand the specific details of the press release, as this filing only serves as a notification of its existence, not its content.
Key Players & Entities
- Abivax S.A. (company) — the registrant filing the 6-K
- January 22, 2024 (date) — date of the 6-K filing and press release issuance
- 001-41842 (other) — Commission File Number for Abivax S.A.
- 7-11 boulevard Haussmann (other) — principal executive office address for Abivax S.A.
Forward-Looking Statements
- The content of the press release (Exhibit 99.1) will contain material information regarding Abivax's operations or financial status. (Abivax S.A.) — high confidence, target: N/A
FAQ
What is the purpose of this 6-K filing by Abivax S.A.?
This 6-K filing by Abivax S.A. serves to report that the registrant issued a press release on January 22, 2024, a copy of which is attached as Exhibit 99.1.
When was the press release mentioned in this filing issued?
The press release mentioned in this filing was issued on January 22, 2024, the same date as the 6-K filing.
Where can investors find the content of the press release referenced in this 6-K?
Investors can find the content of the press release referenced in this 6-K attached as Exhibit 99.1 to the filing.
What is Abivax S.A.'s Commission File Number?
Abivax S.A.'s Commission File Number is 001-41842, as stated in the filing.
Is Abivax S.A. filing annual reports under Form 20-F or Form 40-F?
Abivax S.A. indicates by check mark that it files annual reports under Form 20-F.
Filing Stats: 188 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2024-01-22 06:30:09
Filing Documents
- f6k_012224.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 18KB
- 0001171843-24-000324.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Abivax SA (Registrant) Date: January 22, 2024 /s/ Marc de Garidel Marc de Garidel Chief Executive Officer